Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner
- 22 June 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 9 (8) , 2280-2289
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. To explore the potential of small interfering RNA (siRNA) therapy for NSCLC, we have developed anisamide-targeted LCP to efficiently deliver siRNA into the cytoplasm of sigma receptor-expressing NSCLC cells. Targeted LCP demonstrated a 9-fold higher siRNA delivery efficiency compared to nontargeted LCP in A549 cells in vitro. To simultaneously target multiple oncogenic mechanisms, we coformulated three siRNA sequences targeting HDM2, c-myc and VEGF oncogenes, and investigated their efficacy of cell-killing in A549 and H460 cells in vitro. The results indicated that the pooled siRNA codelivered by the targeted LCP could effectively and simultaneously knock down HDM2, c-myc and VEGF expressions and significantly inhibit tumor cell growth. After iv injection of mice bearing A549 xenografted tumor with Texas Red-labeled siRNA formulated in the targeted LCP, siRNA was successfully delivered to and concentrated in the tumor cells. Repeated intravenous injections of mice with pooled siRNA formulated in the targeted LCP significantly impaired NSCLC growth in vivo (p < 0.01) for both A549 and H460 tumors, demonstrating an ED50 for the treatment of ∼0.2 mg/kg in A549 tumors. The enhanced antitumor activity is due to the fact that the silencing of HDM2/c-myc/VEGF could inhibit tumor proliferation and angiogenesis and also simultaneously induce tumor apoptosis. Our results demonstrate that the targeted LCP is a promising vector to deliver pooled siRNA into tumors and to achieve multiple target blocking. This is potentially a valid therapeutic modality in the gene therapy of human NSCLC.Keywords
This publication has 32 references indexed in Scilit:
- Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung MetastasisMolecular Therapy, 2012
- Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumorJournal of Controlled Release, 2012
- In Vivo Delivery of RNAi with Lipid-Based NanoparticlesAnnual Review of Biomedical Engineering, 2011
- Stealth nanoparticles: High density but sheddable PEG is a key for tumor targetingJournal of Controlled Release, 2010
- Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin LigaseCancer Cell, 2010
- Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA deliveryJournal of Controlled Release, 2010
- Efficient Inhibition of Non-Small-Cell Lung Cancer Xenograft by Systemic Delivery of Plasmid-Encoding Short-Hairpin RNA Targeting VEGFCancer Biotherapy and Radiopharmaceuticals, 2010
- Inhibition of c‐Myc activity by ribosomal protein L11The EMBO Journal, 2007
- Cancer therapeutics: Targeting the dark side of MycEuropean Journal of Cancer, 2005
- Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cellsInternational Journal of Cancer, 2004